BioPharmX Presents Research at Cell Biology 2016 Showing How Molecular Iodine Promotes Breast Health by Attacking Fibrocystic Breast Tissue
- Poster at Cell Biology 2016 will show molecular iodine can inhibit fibrocystic breast tissue cell growth and promote the death of those cells
- Research finds molecular iodine can induce cell death through activation of caspase-independent apoptosis
MENLO PARK, Calif, Dec. 5, 2016 /PRNewswire/ -- BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical company developing products for the dermatology and women's health markets, will share research with the cell biology community next week that identifies the mechanism of action by which molecular iodine can fight fibrocystic breast condition (FBC)
The data will be shared in a poster presentation titled "The Molecular Mechanism of Action of Molecular Iodine on MCF10A Cells from Fibrocystic Breast Tissue," at the ASCB's Cell Biology 2016 in San Francisco, Tuesday.
Results from the in vitro study indicated that molecular iodine had potent inhibitory effects on cell growth and showed an increase in the death MCF10A cells, a human immortalized mammary epithelial cell line derived from fibrocystic breast tissues. The study also found that molecular iodine had no significant impact on healthy cells.
The study found that molecular iodine can induce cell death by activating caspase-independent apoptosis.
"The administration of molecular iodine to patients with FBC reduces swelling and other FBC symptoms," said Lee P. Shulman MD, Professor of Ob/Gyn at the Feinberg School of Medicine of Northwestern University in Chicago, Illinois. "The results indicate that iodine inhibits proliferation of MCF10A cells in vitro, suggesting a potential mechanism of action for molecular iodine in the treatment of symptoms of FBC.
Iodine supplementation has long been recognized in clinics for the treatment of symptoms experienced by patients with FBC, a condition estimated to affect approximately 50 percent of women. Symptoms of FBC include breast swelling, pain, and tenderness. This study is the first to identify molecular iodine's mechanism of action on fibrocystic breast tissue-derived cells.
BioPharmX, Inc., has developed a novel and proprietary formulation sold as Violet® iodine, which consists of iodide and iodate salts that, when exposed to gastric pH, react to form molecular iodine.
- Poster at Cell Biology 2016 will show molecular iodine can inhibit fibrocystic breast tissue cell growth and promote the death of those cells
- Research finds molecular iodine can induce cell death through activation of caspase-independent apoptosis
MENLO PARK, Calif, Dec. 5, 2016 /PRNewswire/ -- BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical company developing products for the dermatology and women's health markets, will share research with the cell biology community next week that identifies the mechanism of action by which molecular iodine can fight fibrocystic breast condition (FBC)
The data will be shared in a poster presentation titled "The Molecular Mechanism of Action of Molecular Iodine on MCF10A Cells from Fibrocystic Breast Tissue," at the ASCB's Cell Biology 2016 in San Francisco, Tuesday.
Results from the in vitro study indicated that molecular iodine had potent inhibitory effects on cell growth and showed an increase in the death MCF10A cells, a human immortalized mammary epithelial cell line derived from fibrocystic breast tissues. The study also found that molecular iodine had no significant impact on healthy cells.
The study found that molecular iodine can induce cell death by activating caspase-independent apoptosis.
"The administration of molecular iodine to patients with FBC reduces swelling and other FBC symptoms," said Lee P. Shulman MD, Professor of Ob/Gyn at the Feinberg School of Medicine of Northwestern University in Chicago, Illinois. "The results indicate that iodine inhibits proliferation of MCF10A cells in vitro, suggesting a potential mechanism of action for molecular iodine in the treatment of symptoms of FBC.
Iodine supplementation has long been recognized in clinics for the treatment of symptoms experienced by patients with FBC, a condition estimated to affect approximately 50 percent of women. Symptoms of FBC include breast swelling, pain, and tenderness. This study is the first to identify molecular iodine's mechanism of action on fibrocystic breast tissue-derived cells.
BioPharmX, Inc., has developed a novel and proprietary formulation sold as Violet® iodine, which consists of iodide and iodate salts that, when exposed to gastric pH, react to form molecular iodine.
